
The catalyst for this renewed interest is the USPTO Appeals Review Panel's Ex parte Chamberlain decision and the Federal Circuit decision on appeal.
Scott A. Warren is a partner at Fox Rothschild LLP and a trusted intellectual property attorney who advises pharmaceutical, biotechnology, chemical, nutraceutical and medical device companies on complex patent matters. With a background in molecular and cancer biology, he counsels clients on patent prosecution, patent term extensions, post-grant proceedings, Hatch-Waxman and biosimilar litigation, trade secrets and global patent portfolio strategy.